WATERTOWN, Mass. - Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company, announced today the commencement of a Phase 2 study to evaluate the safety and efficacy of navacaprant in individuals with bipolar depression. Navacaprant is an investigational oral medication designed as a kappa opioid receptor (KOR) antagonist, which is also in Phase 3 development for major depressive disorder (MDD).
The study is a randomized, double-blind, placebo-controlled trial aiming to assess navacaprant's potential in treating depression associated with bipolar II disorder. Approximately 60 patients with a moderate-to-severe major depressive episode will participate in the trial, with the primary outcome being the change in the Montgomery–Åsberg Depression Rating Scale (MADRS) at Week 6. Secondary endpoints will focus on the impact of navacaprant on anhedonia and other measures.
Navacaprant has previously shown promise in improving depressed mood and anhedonia in MDD during a Phase 2 study. These symptoms are often resistant to current treatments for bipolar depression, highlighting a significant unmet need for patients who typically cycle through multiple therapies without adequate relief.
Dr. Robert Lenz, executive vice president and head of research and development at Neumora, emphasized the importance of exploring new treatments for bipolar depression, where standard care often falls short. Dr. Dan Iosifescu of NYU Grossman School of Medicine supported this view, noting the urgency for novel approaches in the treatment paradigm of bipolar depression.
Neumora expects to report topline data from this Phase 2 study in the second half of 2025. The findings will guide further development of navacaprant for bipolar disorder and potentially other populations within the spectrum of the disorder.
InvestingPro Insights
As Neumora Therapeutics, Inc. (NASDAQ:NMRA) embarks on its Phase 2 study for navacaprant, the company's financial health and market performance provide essential context for investors. According to real-time data from InvestingPro, Neumora has a market capitalization of $1.43 billion. This valuation comes amidst a challenging period for the stock, which has seen a 1-week price total return of -8.66% and a 1-month price total return of -33.92%, indicating recent market pressures.
InvestingPro Tips highlight that Neumora holds more cash than debt on its balance sheet, which is a positive sign for the company's financial stability. This could be crucial as the company funds ongoing clinical trials. Furthermore, the fact that 2 analysts have revised their earnings upwards for the upcoming period suggests growing optimism about the company's future performance despite its stock taking a significant hit over the last week.
It's worth noting that Neumora does not pay a dividend to shareholders, which is typical for clinical-stage biopharmaceutical companies where the focus is on reinvesting earnings into research and development. With the stock trading near its 52-week low, investors may be watching closely for the topline data from the Phase 2 study, which could be a catalyst for the stock.
For those interested in a deeper dive into Neumora's financials and stock performance, InvestingPro offers additional insights, including an extensive list of InvestingPro Tips. To explore these further and make informed investment decisions, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
As Neumora continues to innovate in the field of neuroscience drug development, investors and industry watchers alike will be keenly observing the outcomes of the navacaprant trials, as well as the company's financial trajectory in the dynamic biopharmaceutical market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.